Tacit Therapeutics develops RNA trans-splicing therapies designed to repair defective genes. Their Splicing-Directed Repair™ technology offers a broadly-applicable and non-immunogenic method for treating genetic diseases. The company focuses on maximizing the platform's impact by creating treatments for numerous devastating illnesses, particularly those affecting the brain.
Funding
$9.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetic diseases are caused by mutated RNA, which leads to the production of non-functional or harmful proteins. Traditional gene editing approaches to correct these mutations can be immunogenic and may not be broadly applicable to all types of RNA defects. This limits the availability of effective and safe therapies for a wide range of genetic illnesses.
Solution
Tacit Therapeutics is developing Splicing-Directed Repair™ (SDR) technology, a novel approach to correct mutated RNA using naturally existing cellular components. SDR aims to redirect the flow of genetic information to repair defective genes at the RNA level, thereby creating a non-immunogenic therapeutic strategy. By leveraging the cell's own machinery, SDR offers a broadly applicable and safer alternative to traditional gene editing, with the potential to treat a wide range of genetic diseases. The technology focuses on fixing the RNA, addressing the root cause of the disease while minimizing the risks associated with altering the genome.
Target Audience
The primary target audience includes patients suffering from genetic diseases caused by RNA mutations, as well as pharmaceutical companies and researchers seeking innovative and safe gene therapy approaches.
Features
- Splicing-Directed Repair™ (SDR) technology that repairs mutated RNA.
- Utilizes naturally-existing cellular systems for RNA repair.
- Non-immunogenic approach, reducing the risk of adverse immune responses.
- Broadly applicable to various types of RNA mutations and genetic diseases.
- Aims to correct defective genes at the RNA level, restoring normal protein production.